Spexis AG

Spexis AG

Arzneimittelherstellung

Life-changing therapies for rare disease and oncology patients. Merger between EnBiotix Inc. and Polyphor AG.

Info

Spexis AG (SIX:SPEX) is a publicly-listed Swiss clinical-stage biopharmaceutical company developing rare disease and oncology treatments in indications where new therapeutic options are urgently needed. Spexis AG was launched in December 2021 by the reverse merger of EnBiotix, Inc. (Boston, MA, USA) and Polyphor AG (Allschwil, Switzerland), with EnBiotix shareholders resulting in the majority. Our focus is on chronic respiratory diseases (CRD), and our lead product candidate ColiFin® is P3 ready. ColiFin® is an inhaled colistimethate sodium product in-licensed from PARI Pharma GmbH for ex-European rights. Approved and marketed in Europe as a front-line therapy in cystic fibrosis (“CF”) patients, ColiFin® already has a proven safety, efficacy, and commercial track record. In the U.S., ColiFin® has Orphan Drug and Qualified Infectious Disease Product (“QIDP”) designations, which together will provide a total of 12 years of market exclusivity from NDA approval. We also have a “Study May Proceed” letter from the FDA regarding a single phase 3 study evaluating ColiFin® in CF patients being sufficient to support a future New Drug Application (“NDA”). The trial design has been endorsed by the Cystic Fibrosis Foundation (CFF) Therapeutic Development Network (TDN), the clinical development arm of the CFF. Of note, the CFF also invested in the pre-merger financing launching Spexis.

Branche
Arzneimittelherstellung
Größe
11–50 Beschäftigte
Hauptsitz
Allschwil
Art
Kapitalgesellschaft (AG, GmbH, UG etc.)
Gegründet
1996

Orte

Beschäftigte von Spexis AG

Updates

  • Unternehmensseite von Spexis AG anzeigen, Grafik

    5.001 Follower:innen

    We are excited to announce that we have completed the sale of our thanatin-outer membrane protein-targeting antibiotics (OMPTA) program to Basilea Pharmaceutica Ltd, a global leader in anti-infectives discovery & development. This is the third major corporate transaction on our highly diverse and well characterized macrocycle library, further validating its potential as a drug discovery engine in oncology & rare disease. Read the full announcement here: https://lnkd.in/eUanzURe

    • Kein Alt-Text für dieses Bild vorhanden

Ähnliche Seiten